At the same time, the UPLC‐MS/MS assay was used to screen the active components of JPHTF in the serum, and the key potential compounds involved in reversing trastuzumab resistance of JPHTF in HER2‐positive gastric cancer were identified and validated in vivo and vitro. The gene discussed is ERBB2; the disease is gastric cancer.